SCHEMBL5507775

SCHEMBL5507775

NC(=O)c1ccc(-c2cnc(N(Cc3ccc(C(F)(F)P(=O)(O)O)c(Br)c3)c3ccc(F)cc3)o2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 11/20 0.38
PTPN2 P17706 6/20 0.38
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
NFKB1 P19838 1/20 0.36
CYP2C19 P33261 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SENP8 Q96LD8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5499284 0.89 SSTR5 (0.34) PTPN1PTPN2KDM4ENPC1ALDH1A1
SCHEMBL5499287 0.88 PTPN2 (0.33) PTPN1PTPN2KDM4ENPC1ALDH1A1
SCHEMBL5499376 0.87 PTPN1 (0.39) PTPN1PTPN2FAAHPTPRC
SCHEMBL5499270 0.87 PTPN1 (0.44) PTPN1PTPN2FAAHHDAC1HDAC6
SCHEMBL5502408 0.86 PTPN1 (0.42) PTPN1PTPN2
SCHEMBL5505384 0.86 PTPN1 (0.40) PTPN1PTPN2CYP2C9CYP2C19
SCHEMBL5988073 0.86 PTPN1 (0.40) PTPN1PTPN2NPC1GAARAB9A
SCHEMBL5499142 0.83 PTPN1 (0.41) PTPN1PTPN2FAAHHDAC1HDAC6
SCHEMBL5499814 0.83 PTPN1 (0.39) PTPN1PTPN2FAAHPTPRC
SCHEMBL5988122 0.83 PTPN1 (0.39) PTPN1PTPN2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786421-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-05-23 EP disclosed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed
WO-2006017124-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases PTPRO, PTPRG, PTPN1 PTPN1 3/4885PTPN2 24/4885KDM4E 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.